Project Grant R43EY036298
Award Date
9/30/24
Completion Date
8/31/25
Dollars Obligated
$730K
Federal Agency
National Eye Institute
Awardee
Human Cell Co (F4N9XZWABV33)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
This $251,250 Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports research to characterize inflammatory cell infiltration in the meibomian glands and investigate the role of autoimmune CD4+ T cells in causing meibomian gland dysfunction (MGD), a leading cause of dry eye disease affecting millions. The award funds a collaborative research project between Baylor College of Medicine, which serves as the prime recipient, and the University of Houston College of...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This Project Grant award of $422,199 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to explore a new therapeutic approach for treating meibomian gland dysfunction (MGD), a leading cause of dry eye disease. The research aims to investigate the use of estrogen receptor (ER) inhibitors, such as tamoxifen and fulvestrant, to suppress ER activity and increase androgen receptor (AR) function in the meibomian glands, with the goal of enhancing...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to advance the development of the drug filociclovir (FCV) for the treatment of adenoviral conjunctivitis and epidemic keratoconjunctivitis. The $674,963 award to Microbiotix, Inc. will fund the completion of key preclinical activities, including finalizing the eye drop formulation, conducting IND-enabling toxicology studies in rabbits and rats, and completing regulatory...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $310,952 to Bedrock Therapeutics, Inc. to develop a novel gene therapy treatment for neovascular age-related macular degeneration (NAMD). The key objectives are to produce the BDRK-501 gene therapy candidate, establish potency assays, and evaluate the efficacy of BDRK-501 in a rat model of NAMD. BDRK-501 combines Bedrock's AAV vector technology and a proprietary HLA-G-based immunomodulatory...
This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
This federal Project Grant awarded by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), aims to develop a safe and effective topically administered pharmacotherapy to treat acute corneal pain. The $590,172 award to Vyluma Inc., with a period of performance from Sep 30, 2024 to Aug 31, 2025, will support three specific research aims: 1) a pharmacodynamic dose identification study to determine the minimum effective dose of the pregabalin-based...